Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs

Novo Nordisk's stock declined up to 7% in trading on January 14, 2026. The company announced a $23 billion sales target for its obesity drugs, including Wegovy and Ozempic. The stock decline occurred despite the sales forecast.

Next story